Printer Friendly

Evaluation of ADAM33 gene's single nucleotide polymorphism variants against asthma and the unique pattern of inheritance in Northern and Central Punjab, Pakistan.

Asthma is a chronic respiratory disorder characterized by inflammation and excessive mucosal secretion leading to airflow restriction and bronchial hyper responsiveness, consequently resulting in irreversible structural changes and airway remodeling. The prevalence of asthma is increasing globally, and it is anticipated that asthma, along with chronic obstructive pulmonary disease (COPD), may become the third leading cause of global mortality in the near future. (1,2) The prevalence of allergic and respiratory disorders has increased substantially in Pakistan, and the current percentage of physician-diagnosed asthma patients is about 9.5%; however, this number is continuously increasing in line with trends in other Asian countries. (3,4) Asthma is a polygenic disease triggered by a complex interplay between environmental and genetic factors, leading to diverse phenotypes with variable severity and atopic reactions. (5-7) Increased familial aggregation of the disease, as shown by the observed increase in concordance in monozygotic twins relative to that in dizygotic twins, is an indicator of major genetic/ genomic influence on asthma disease development. (8) More than 100 genomic loci have been reported to be linked with asthma disease susceptibility; (2) among them ADAM33 is a major asthma susceptible candidate gene. (9)

The ADAM33 gene was first reported in an outbred population as an asthma manifestation-associated gene. (10) It contains 23 exons and is extended over a 14-kb region of chr. 20p13. It encodes the membrane-anchored enzyme disintegrin and metalloproteinase domain-containing protein 33, which influences the activity of growth factors and cytokines that are involved in the remodeling of airways. (10,11) ADAM33 has been extensively studied as an asthma risk factor because of its likely role in cell differentiation, abnormal proliferation, and airway remodeling. (12,13) The single nucleotide polymorphisms (SNPs) of ADAM33 gene have been studied in subjects of various ethnicities, but the strength of the association of these variants with asthma development has been found to vary in different populations, and several studies have reported contradictory results regarding the association of these SNPs within sub-ethnic groups of the same population. (3,8)

In previous studies, the rs2280089, rs2280090, and rs2280091 SNP variants have shown significant as well as non-significant associations with asthma susceptibility in different asthmatic populations in Asia. (14,15) Owing to the conflicting and variable results regarding the impact of these SNP variants of ADAM33 in manifestation of asthma, (8,16) the current study was designed to determine the probable role of 3 SNP variants [rs2280089, rs2280090, and rs2280091] of ADAM33 in the pathogenesis of asthmatic complications in a local population of Northern and Central Punjab, Punjab, Pakistan.

Methods. A total of 296 clinically diagnosed asthma patients and 343 normal healthy participants from Northern and Central Punjab (Table 1) were enrolled for this study between 2015 and 2017. The asthma patients were selected from Asthma and Allergy Clinics for collecting peripheral blood samples after being diagnosed by pulmonologists. Healthy control participants without any history of allergy, atopy, asthma, or other severe diseases, were randomly recruited from the general population for this case-control association study.

This study was approved by the Ethical/Institutional Review Board of The Children's Hospital & Institute of Child Health, Lahore and the University of the Punjab, Lahore, Pakistan. Signed informed consent, written in the local language, was obtained from recruited study participants or guardians in case of minors and all experiments were in accordance with the Helsinki Declaration.

Asthmatic patients with a history of any sickness involving the airway/lungs, such as emphysema, chronic bronchitis, pneumonia, tuberculosis, and so forth were excluded from this study. A detailed history was recorded for the non-asthma controls to exclude participants with any history of pulmonary disorders, allergies, or a family history of such diseases.

Single nucleotide polymorphism detection strategies. In current case-control study, target SNP variants were studied principally by candidate gene approach. Different strategies are generally adapted to study SNP variants in candidate gene approach based upon availability of financial resources and research instruments. Restriction Fragment Length Polymorphism (RFLP), allele specific primers, real time polymerase chain reaction (PCR), SNaPshot (single base extention method) and DNA sequencing are most popular strategies to study SNP variants in candidate gene approach. (8,15,17,18) However we have adapted DNA sequencing strategy which is little bit expensive than other techniques but it is most reliable technique for detection of SNPs.

Deoxyribonucleic acid extraction and sequencing. Genomic DNA was extracted from blood samples using a previously described organic extraction method. (19) Target SNPs of ADAM33 were analyzed using capillary-based sequencing on GA-3130XL (Applied Biosystems, Foster City, CA, USA). Single nucleotide polymorphisms regions were first amplified by PCR in a 20 [micro]L reaction volume containing 20 ng DNA, 1 [micro]L primer pair (8 [micro]M each), and 10 [micro]L 2x ready reaction PCR mix (EZ D-PCR MASTER MIX, Bio Basic, Canada). Amplified PCR products were purified by HighPrep PCR Clean Up kit (MagBio Genomics, USA), and the purified PCR amplicons were used as templates for sequencing PCR. Big Dye kit ver. 3.1 (Thermo Fisher Scientific, USA) was used for sequencing, and the products were further analyzed on GA-3130XL (Applied Biosystems, USA). Sequencing results were analyzed and interpreted by Sequencing Analysis 5.1 software (Applied Biosystems) (Table 2).

Statistical analysis. SHEsis software, a powerful platform used for the analysis of linkage disequilibrium (LD), haplotype construction and genetic associations with polymorphic genomic loci, (20) was used to analyze the allele frequencies, genotype frequencies, LD, and to perform haplotype construction. Haploview software version 4.2 was also used to verify the LD and haplotype results. The cutoff value was selected as p=0.05.

Results. Allele and genotype frequencies. Allele and genotype frequencies of participants are given in Table 3. No significant association was observed between the investigated SNPs and asthma in either the allelic or genotyping models. The association of these SNPs with asthma was also studied after performing population stratification. No association was observed at the sub-population level for Central or Northern Punjab. The association was also non-significant for study participants belonging to those groups, who were placed in category "others." Similarly, no associations were observed after population stratification based on age, gender, family history of asthma, or urban/rural/ semi-urban populations.

Linkage disequilibrium analysis. Linkage disequilibrium analysis revealed a very strong linkage between the studied SNPs in the population under investigation (Figure 1). There were no significant differences between the allele frequencies in either the asthmatic or control samples; for this reason, LD blocks were generated in a mixed population after excluding samples with missing genotype results (n=294 case, n=342 controls). Interestingly all 3 SNPs showed high LD (D' [greater than or equal to] 0.994, [r.sup.2] [greater than or equal to] 0.983), even after population stratification. These SNPs followed a fixed inheritance pattern, as shown in Table 4.

Haplotypes. Haplotypes were generated in SHEsis software by considering 0.03 as lowest frequency threshold in haplotype analysis (Table 5).

Discussion. Different polymorphic variants of ADAM33 have been reported to show both a significant and non-significant association with asthma susceptibility in diverse populations. However, its potential genetic association with asthma cannot be ignored, because the investigated polymorphic variants may also be independently or collectively associated with the pathogenesis of asthma. However, the varying results in ethnically different populations suggest that association of polymorphic variants of ADAM33 with asthma differs according to ethnicity. (12,15)

In previous studies, the rs2280089, rs2280090, and rs2280091 SNP variants have shown significant as well as non-significant associations with asthma susceptibility. (14) In the current case-control study, an analysis of these variants revealed that the minor allele and genotype frequencies showed no noticeable differences, indicating that the rs2280089, rs2280090, and rs2280091 markers may not be independently associated with asthma in the study population. Population stratification analysis demonstrated that there was no significant association for ethnic-specific participants in the Central Punjab, Northern Punjab, and "others". The allele and genotype frequencies of these variants were also found to be non-significant after stratification based on age, gender, family history of asthma in asthmatics, and urban/rural/semi-urban population. Despite the reported significant associations of these SNPs with asthma in multiple populations, no significant association has been identified in sub-ethnic populations of the same origin. (8,14,16,23) A recent study based on 2 cities of Pakistan (Islamabad and Lahore) reported a protective role of rs2280091 against asthma in a Pakistani population. (24) As the study was based in Islamabad city, the capital of Pakistan, the participants included an admixture of different ethnicities within Pakistan. It is highly probable that the major component of the study population originated from Islamabad (not described in that study), which may be the reason why our results differed from those in the previous study. However, ethnicity-based studies in other provinces of Pakistan are required to improve our understanding of the role of the studied SNPs in the development of asthma.

The observed non-significant association with asthma in a Northern and Central Punjabi population was consistent with the results of our previous study, which was specific to the Lahore region. (25) Linkage disequilibrium analysis is used to determine the combination of alleles at proximal genomic regions, which may predict non-random associations of investigated alleles at proximal loci. (26) A very strong LD (D' >0.99) was observed in the SNPs studied here (rs2280089, rs2280090, rs2280091) in all subjects, suggesting that these SNPs are inherited together. Similarly, a strong LD (D' >0.99) was observed after population stratification based on age, gender, family history of asthma, urban/rural/semi-urban population, Northern Punjab, Central Punjab, and others. There was no observed difference in allele combinations in the studied participants, excluding a single healthy participant (ID= SGD-CNT-18, Female) who was recruited from Sargodha and belonged to the ethnically Awan family of Northern Punjab. All study participants, excluding SGD-CNT-18, followed the same allele inheritance pattern with 3 combinations: Pattern-1, GG GG AA; Pattern-2, AG AG AG; and Pattern-3, AA AA GG, for the 3 investigated SNPs (Table 4). This inheritance pattern has not been previously observed in a Northern and Central Punjabi population.

Qu et al (27) investigated the same 3 SNPs in a Northern Chinese population, and reported that rs2280089 and rs2280091 were significantly associated with asthma, whereas rs2280090 was not significantly associated with asthma in a pediatric population. However, a strong LD among these SNPs was not observed, contrary to the findings in our population. Another recent study on a Chinese Li (23) population reported the significant association of rs2280089, and the non-significant association of rs2280091 with susceptibility to asthma. The same study also predicted a low LD between the SNP variants in the Li population. These findings of a low LD for the target SNPs were also reported in others populations, including Mongolians and Egyptians. (28,29)

A Saudi Arabian population-based study previously reported a significant association between the rs2280091 and rs2280090 SNP variants and asthma susceptibility, which is contradictory to the current findings; however, that study also reported a strong LD between the 2 variants, consistent with the findings of our study. (30) A recent study on a Southwestern Iranian population also reported similar results to those of the current study regarding the non-significant association of rs2280089 and rs2280091 with asthma disease, as well as a strong LD between these SNPs. (8) Zeinaly et al also have reported the non-significant association of rs2280091 SNP with asthma in Azerbaijan Population of Iran. (15)

Study limitations. Punjab province of Pakistan is an admixture of populations that is culturally similar but even though ethnically/linguistically and genetically different races/tribes live in different regions of Pakistani-Punjab. Our study mainly covered Northern and Central Punjab with limited sample size; therefore, studies with increased sample size are suggested from different regions of Punjab which may help in better understanding the role of ADAM33 gene's SNP variants against asthma susceptibility.

In conclusion, we did not find any significant association of the rs2280089, rs2280090 and rs2280091 SNPs with susceptibility to asthma in allelic or genotypic models in this Central and Northern Punjabi population. Haplotype analyses results were also nonsignificant for these SNPs in terms of asthma susceptibility. The findings of this study report a very strong LD among the studied SNPs, along with a statistically non-significant association with asthma disease in Northern and Central Punjab. These findings support the hypothesis that genetic association of ADAM33 gene's polymorphic variants against asthma susceptibility is ethnicity-specific. Further similar studies may enhance our ethnicity-based knowledge regarding asthma progression in order to develop customized approaches for more accurate diagnosis and prognosis in ethnically varied populations.

[Please note: Some non-Latin characters were omitted from this article.]

doi: 10.15537/smj.2019.8.24411

Acknowledgment. We would like to thank Editage (www. for English language editing.


(1.) Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol 2017; 17: 99-103.

(2.) Sabar MF, Akram M, Awan FI, Ghani MU, Shahid M, Iqbal Z, et al. Awareness of Asthma Genetics in Pakistan: A review with some recommendations. Adv Life Sci 2018; 6: 1-10.

(3.) Ghani MU, Sabar MF, Shahid M, Awan FI, Akram M. A report on asthma genetics studies in Pakistani population. Adv Life Sci 2017; 4: 33-38.

(4.) Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy 2014; 4: 75-85.

(5.) Sabar MF, Shahid M, Bano I, Ghani MU, Akram M, Iqbal F, et al. rs12603332 is associated with male asthma patients specifically in urban areas of Lahore, Pakistan. J Asthma 2017; 54: 887-892.

(6.) Godar M, Lambrecht BN. A New aDENNDum to genetics of childhood asthma. Cell 2016; 164: 11-13.

(7.) Best LG, O'Leary RA, O'Leary MA, Yracheta JM. Humoral immune factors and asthma among American Indian children: a case-control study. BMC Pulm Med 2016; 16: 93.

(8.) Farjadian S, Moghtaderi M, Hoseini-Pouya BA, Ebrahimpour A, Nasiri M. ADAM33 gene polymorphisms in Southwestern Iranian patients with asthma. Iran J Basic Med Sci 2018; 21: 813-817.

(9.) Ghani MU, Sabar MF, Bano I, Shahid M, Akram M, Khalid I, et al. Inheritance pattern of Rs2280089, Rs2280090, Rs2280091 Snp Variants in Punjabi Population and Association with Asthma Disease. Chest 2019; 155: 168A.

(10.) Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyper responsiveness. Nature 2002; 418: 426-430.

(11.) Tripathi P, Awasthi S, Gao P. ADAM metallopeptidase domain 33 (ADAM33): a promising target for asthma. Mediators Inflamm 2014; 2014: 572025.

(12.) Sabar MF, Ghani MU, Shahid M, Sumrin A, Ali A, Akram M, et al. Genetic variants of ADAM33 are associated with asthma susceptibility in the Punjabi population of Pakistan. J Asthma 2016; 53: 341-348.

(13.) Shalaby SM, Abdul-Maksoud RS, Abdelsalam SM, Abdelrahman HM, Abdelaziz Almalky MA. ADAM33 and ADAM12 genetic polymorphisms and their expression in Egyptian children with asthma. Ann Allergy Asthma Immunol 2016; 116: 31-36.

(14.) Deng R, Zhao F, Zhong X. T1 polymorphism in a disintegrin and metalloproteinase 33 (ADAM33) gene may contribute to the risk of childhood asthma in Asians. Inflamm Res 2017; 66: 413-424.

(15.) Zeinaly I, Sadeghi-Shabestrai M, Babaloo Z, Razavi A, Sajay-Asbaghi M, Sadigh-Eteghad S, et al. Investigating the Association of ADAM33 Single Nucleotide Polymorphisms (SNPs) with Susceptibility to Allergic Asthma in Azerbaijan Population of Iran: A Case-control Study. Iran J Allergy Asthma Immunol 2017; 16: 378-385.

(16.) Sun FJ, Zou LY, Tong DM, Lu XY, Li J, Deng CB. Association between ADAM metallopeptidase domain 33 gene polymorphism and risk of childhood asthma: a meta-analysis. Braz J Med Biol Res 2017; 50: e6148.

(17.) Shahid M, Tayyab U, Kousar S, Ghani MU, Sabar MF, Husnain T. Rs153109 as Possible Indicator of Effectiveness of Vitamin D Supplements for Suppressing Copd Symptoms. Chest 2019; 155: 219A.

(18.) Souto L. A comparison of SNaPshot minisequencing and HRM analysis in mtSNP genotyping with reference samples from East Timor. J Genet Genome Res 2015; 2: https://doi. org/10.23937/2378-3648/1410021

(19.) Shahid M, Sabar MF, Bano I, Rahman Z, Iqbal Z, Fatim Ali SS, et al. Sequence variants on 17q21 are associated with the susceptibility of asthma in the population of Lahore, Pakistan. J Asthma 2015; 52: 777-784.

(20.) Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98.

(21.) Duan Y, Long J, Chen J, Jiang X, Zhu J, Jin Y, et al. Overexpression of soluble ADAM33 promotes a hypercontractile phenotype of the airway smooth muscle cell in rat. Exp Cell Res 2016; 349: 109-118.

(22.) Davies ER, Kelly JF, Howarth PH, Wilson DI, Holgate ST, Davies DE, et al. Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life. JCI Insight 2016; 1: (11).

(23.) Shen B, Lin R, Wang CC, Rei J, Sun Y, Yang YL, et al. ADAM33 gene polymorphisms identified to be associated with asthma in a Chinese Li population. Biomed Rep 2017; 6: 323-328.

(24.) Saba N, Yusuf O, Rehman S, Munir S, Noor A, Saqlain M, et al. Single nucleotide polymorphisms in asthma candidate genes TBXA2R, ADAM33 FCER1B and ORMDL3 in Pakistani asthmatics a case control study. Asthma Res Pract 2018; 4: 4.

(25.) Sabar MF, Ghani MU, Shahid M, Sumrin A, Ali A, Akram M, et al. Genetic variants of ADAM33 are associated with asthma susceptibility in the Punjabi population of Pakistan. J Asthma 2016; 53: 341-348.

(26.) Sved JA, Hill WG. One hundred years of linkage disequilibrium. Genetics 2018; 209: 629-636.

(27.) Qu S, Sun D, Wang Y, Zhang C, Lv Y, Yao L. Association of ADAM33 polymorphisms with childhood asthma in a northern Chinese population. Exp Mol Pathol 2011; 91: 775-779.

(28.) Zhu SF, Li JG. [Association between polymorphism of ADAM33 gene and bronchial asthma in Mongolian population]. Zhonghua Yi Xue Za Zhi 2016; 96: 2791-2795. [Chinese]

(29.) El-Falaki MM, Wilson MM, Ezzat GM, Mokhtar DA, El Baz MS, Hamed DH. A disintegrin and metalloproteinase 33 (ADAM33) gene polymorphism association with asthma in Egyptian children. Egypt J Med Hum Genet 2013; 14: 55-62.

(30.) Al-Khayyat AI, Al-Anazi M, Warsy A, Vazquez-Tello A, Alamri AM, Halwani R, et al. T1 and T2 ADAM33 single nucleotide polymorphisms and the risk of childhood asthma in a Saudi Arabian population: a pilot study. Ann Saudi Med 2012; 32: 479-486.

Muhammad U. Ghani, M.Phil, Muhammad F. Sabar, PhD, Iqbal Bano, MBBS, FCPS, Mariam Shahid, M.Phil, PhD, Muhammad Akram, M.Phil, Ifrah Khalid, BS, M.Phil, Alishba Maryam, B.S, M.Phil, Muhammad U. Khan, M.Phil.

From the Centre for Applied Molecular Biology (Ghani, Sabar, Akram, Khalid, Maryam, Khan), from the Centre of Excellence in Molecular Biology, (Shahid), University of the Punjab, and from the The Children's Hospital & The Institute of Child Health (Bano), Lahore, Pakistan.

Received 2nd May 2019. Accepted 16th July 2019.

Address correspondence and reprint request to: Dr. Muhammad F. Sabar, Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan. E-mail:

ORCID ID: 0000-0003-0135-2991

Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

Caption: Figure 1--Linkage disequilibrium (LD) block generated using Haploview software. Minimum genotyping call rate for all 3 single nucleotide polymorphisms (SNPs) was 90%. All samples, including cases and controls, were used for this analysis
Table 1--Demographics data of study participants.

Description                 Case   Control

Total no. of samples        296      343
Central Punjab              150      172
North Punjab                 37      51
Others *                    109      120
Kids age <14                168      144
Participants age >14         95      122
Male                        130      173
Female                      100      126

* Participants recruited from Northern and Central Punjab but belonged
to other parts of Punjab/Pakistan or missing information related to
residential area.

Table 2--Amplification primer sequences.

Target SNP   Primer ID   Primer       3' sequence

rs2280089    Usman-07F   LEFT     CTGCTGGGCTCATGAGAGTT
rs2280090                PRIMER
rs2280091    Usman-07R   RIGHT    GAGCTGAGAGGGTGACTTGG

Target SNP    Length of    PCR Product
             primer (bp)   length (bp)

rs2280089        20            442
rs2280091        20

SNP--single nucleotide polymorphism, PCR--polymerase chain reaction

Table 3--Allele and genotype frequencies of study participants.

Participant       SNP       Minor        MAF/genotype
Category                   allele/       frequency in
                           genotype         cases

All            rs2280089   A          0.180
participants               AA/AG/GG   0.017/ 0.327/0.656
               rs2280090   A          0.181
                           AA/AG/GG   0.017/0.328/0.655
               rs2280091   G          0.182
                           AA/AG/GG   0.652/0.331/0.017
Central        rs2280089   A          0.180
Punjab                     AA/AG/GG   0.027/0.307/0.667
               rs2280090   A          0.180
                           AA/AG/GG   0.027/0.307/0.667
               rs2280091   G          0.183
                           AA/AG/GG   0.660/0.313/0.027
North          rs2280089   A          0.214
Punjab                     AA/AG/GG   0.029/0.371/0.600
               rs2280090   A          0.216
                           AA/AG/GG   0.027/0.378/0.595
               rs2280091   G          0.216
                           AA/AG/GG   0.595/0.378/0.027
Orther         rs2280089   A          0.173
Punjab/                    AA/AG/GG   0.00/0.346/0.661
Pakistan       rs2280090   A          0.170
                           AA/AG/GG   0.00/0.339/0.661
               rs2280091   G          0.170
                           AA/AG/GG   0.661/0.339/0.00
Children age   rs2280089   A          0.176                ]
<14 years                  AA/AG/GG   0.018/0.315/0.667
               rs2280090   A          0.176
                           AA/AG/GG   0.018/0.315/0.667
               rs2280091   G          0.176
                           AA/AG/GG   0.667/0.315/0.018
Participants   rs2280089   A          0.176
age                        AA/AG/GG   0.022/0.309/0.670
>14 years      rs2280090   A          0.174
                           AA/AG/GG   0.021/0.305/0.674
               rs2280091   G          0.174
                           AA/AG/GG   0.674/0.305/0.021

Participant       SNP       Minor       MAF/Genotype      Pearson's
Category                   allele/      frequency in       P-value
                           genotype       controls

All            rs2280089   A          0.156               0.246
participants               AA/AG/GG   0.017/0.277/0.706   0.395
               rs2280090   A          0.158               0.276
                           AA/AG/GG   0.020/0.275/0.705   0.340
               rs2280091   G          0.157               0.234
                           AA/AG/GG   0.703/0.280/0.017   0.372
Central        rs2280089   A          0.137               0.131
Punjab                     AA/AG/GG   0.012/0.250/0.738   0.288
               rs2280090   A          0.137               0.131
                           AA/AG/GG   0.012/0.250/0.738   0.288
               rs2280091   G          0.137               0.105
                           AA/AG/GG   0.738/0.250/0.012   0.243
North          rs2280089   A          0.235               0.746
Punjab                     AA/AG/GG   0.020/0.431/0.549   0.839
               rs2280090   A          0.245               0.654
                           AA/AG/GG   0.039/0.412/0.549   0.89
               rs2280091   G          0.235               0.765
                           AA/AG/GG   0.549/0.431/0.87    0.87
Orther         rs2280089   A          0.150               0.564
Punjab/                    AA/AG/GG   0.025/0.250/0.725   0.098
Pakistan       rs2280090   A          0.151               0.591
                           AA/AG/GG   0.025/0.252/0.723   0.103
               rs2280091   G          0.154               0.651
                           AA/AG/GG   0.717/0.258/0.025   0.119
Children age   rs2280089   A          0.156               0.518
<14 years                  AA/AG/GG   0.021/0.271/0.708   0.685
               rs2280090   A          0.156               0.518
                           AA/AG/GG   0.021/0.271/0.708   0.685
               rs2280091   G          0.156               0.518
                           AA/AG/GG   0.708/0.271/0.021   0.685
Participants   rs2280089   A          0.143               0.363
age                        AA/AG/GG   0.008/0.270/0.721   0.571
>14 years      rs2280090   A          0.149               0.482
                           AA/AG/GG   0.017/0.264/0.719   0.767
               rs2280091   G          0.148               0.459
                           AA/AG/GG   0.713/0.279/0.008   0.641

Participant       SNP       Minor          Odd ratio
Category                   allele/         [95% CI]/
                           genotype        Chi-square

All            rs2280089   A          1.190 [0.886-1.597]
participants               AA/AG/GG   1.857
               rs2280090   A          1.176 [0.877-1.577]
                           AA/AG/GG   2.153
               rs2280091   G          0.837 [0.624-1.122]
                           AA/AG/GG   1.973
Central        rs2280089   A          1.387 [0.906-2.123]
Punjab                     AA/AG/GG   2.487
               rs2280090   A          1.387 [0.906-2.123]
                           AA/AG/GG   2.487
               rs2280091   G          0.704 [0.46-1.077]
                           AA/AG/GG   2.823
North          rs2280089   A          0.886 [0.426-1.842]
Punjab                     AA/AG/GG   0.349
               rs2280090   A          0.849 [0.416-1.735]
                           AA/AG/GG   0.231
               rs2280091   G          1.115 [0.543-2.287]
                           AA/AG/GG   0.277
Orther         rs2280089   A          1.158 [0.702-1.910]
Punjab/                    AA/AG/GG   4.628
Pakistan       rs2280090   A          1.147 [0.695-1.892]
                           AA/AG/GG   4.541
               rs2280091   G          0.891 [0.541-1.466]
                           AA/AG/GG   4.251
Children age   rs2280089   A          1.150 [0.7523-1.758
<14 years                  AA/AG/GG   0.756
               rs2280090   A          1.150 [0.752-1.758]
                           AA/AG/GG   0.756
               rs2280091   G          0.869 [0.568-1.329]
                           AA/AG/GG   0.756
Participants   rs2280089   A          1.271 [0.756-2.136]
age                        AA/AG/GG   1.119
>14 years      rs2280090   A          1.202 [0.717-2.014]
                           AA/AG/GG   0.528
               rs2280091   G          0.823 [0.491-1.379]
                           AA/AG/GG   0.887

MAF--full meaning, SNP--single nucleotide polymorphism

Table 4--Inheritance pattern in enrolled study participants.

Enrolled study      Description   rs2280089   rs2280090   rs2280091

All enrolled study   Pattern-1       GG          GG          AA
excluding a sample   Pattern-2       AG          AG          AG
(* SGD-CNT-18)
                     Pattern-3       AA          AA          GG
* SGD-CNT-18         Pattern-4       AG          AA          AG

* SGD-CNT-18 is a male control participant enrolled from Sargodha

Table 5--Haplotype analyses.

Haplotype    Case    Control   [Chi.sup.2]
            (freq)   (freq)

A A G *     0.180     0.156       1.267
G G A *     0.818     0.841       1.267

Haplotype   Pearson's   Odds ratio [95%CI]

A A G *       0.260     1.184 [0.882-1.590]
G G A *       0.260     0.844 [0.629-1.134]
COPYRIGHT 2019 Saudi Medical Journal
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ghani, Muhammad U.; Sabar, Muhammad F.; Bano, Iqbal; Shahid, Mariam; Akram, Muhammad; Khalid, Ifrah;
Publication:Saudi Medical Journal
Geographic Code:9PAKI
Date:Aug 1, 2019
Previous Article:Identification of FBXW7[alpha]-regulated genes in M1-polarized macrophages in colorectal cancer by RNA sequencing.
Next Article:Survival of mechanically ventilated patients admitted to intensive care units: Results from a tertiary care center between 2016-2018.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters